Induction with levomethadyl acetate. Safety and efficacy

Archives of General Psychiatry

Volumn 55, Issue 8, 1998, Pages 729-736

  Jones, Hendrée E ^a   Strain, Eric C ^a   Bigelow, George E ^a   Walsh, Sharon L ^a   Stitzer, Maxine L ^a   Eissenberg, Thomas ^a,b   Johnson, Rolley E ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c Roxane Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVACETYLMETHADOL; METHADONE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; OPIATE ADDICTION; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANALGESICS, OPIOID; ATTITUDE TO HEALTH; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHADYL ACETATE; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; PATIENT DROPOUTS; QUESTIONNAIRES; SUBSTANCE ABUSE DETECTION; TREATMENT OUTCOME;

EID: 0031904343     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.55.8.729     Document Type: Article

References (28)

1. Ling W, Rawson RA, Compton MA. Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. J Psychoactive Drugs. 1994;26:119-128.
2. Fraser HG, Isbell H. Actions and addiction liabilities of alpha-acetyl-methadol in man. J Pharmacol Exp Ther. 1952;105:458-465.
3. Henderson GL. Pharmacodynamics of LAAM in man: plasma levels of LAAM and its metabolites following acute and chronic administration in man (fourth-and sixth-quarter progress reports), 1974-1975. In: Blaine JD, Renault P, eds. Rx: 3x/Week LAAM-Alternative to Methadone: NIDA Research Monograph 8. Rockville, Md: National Institute on Drug Abuse; 1976:64-65.
4. Billings RE, McMahon RE, Blake DA. I-Acetylmethadol (LAM) treatment of opiate dependence: plasma and urine levels of two pharmacologically active metabolites. Life Sci. 1974;14:1437-1446.
5. Ling W, Charuvastra VC, Klett CJ. Current status of the evaluation of LAAM as a maintenance drug for heroin addicts. Am J Drug Alcohol Abuse. 1975;2:307-315.
6. Ling W, Charuvastra C, Kaim S, Klett J. Methadyl acetate and methadone as maintenance treatments for heroin addicts. Arch Gen Psychiatry. 1976;33:709-720.
7. Ling W, Klett JC, Gillis RD. A cooperative clinical study of methadyl acetate, I: three times-a-week regimen. Arch Gen Psychiatry. 1978;35:345-353.
8. Senay EC, Dorus W, Renault RF. Methadyl acetate and methadone: an open comparison. JAMA. 1977;237:138-142.
9. Savage C, Karp EG, Curran SF, Hanlon TE, McCabe LO. Methadone/LAAM maintenance: a comparison study. Comp Psychiatry. 1976;17:415-424.
10. Zangwell BC, McGahan P, Dorozynsky L, McLellan AT. How effective is LAAM treatment? clinical comparison with methadone. In: Harris LS, ed. Problems of Drug Dependence, 1985: NIDA Research Monograph 67. Rockville, Md: National Institute on Drug Abuse; 1985.
11. Swan N. States slow to approve LAAM. NIDA Notes. 1994;9:12-13.
12. Prendergast ML, Grella C, Perry SM, Anglin MD. Levo-alpha-acetylmethadol (LAAM): clinical, research and policy issues of a new pharmacotherapy for opioid addiction. J Psychoactive Drugs. 1995;27:239-247.
13. Judson BA, Goldstein A. Levo-alpha-acetylmethadol (LAAM) in the treatment of heroin addicts, I: dosage schedule for induction and stabilization. Drug Alcohol Depend. 1979;4:461-466.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
15. Eissenberg T, Bigelow GE, Strain EC, Walsh SL, Brooner RK, Stitzer ML, Johnson RE. Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence: a randomized clinical trial. JAMA. 1997;277:1945-1951.
16. Spitzer RL, Williams JBW, Gibbon M. Instruction Manual for the Structured Clinical Interview for DSM-III-R. New York, NY: New York State Psychiatric Institute; 1987.
17. McLellan AT, Luborsky LK, Woody GE, O'Brien CP, Druley KA. Predicting response to alcohol and drug abuse treatments. Arch Gen Psychiatry. 1983;40: 620-625.
18. Woody GC, McLellan AT, Luborsky L, O'Brien CP. Sociopathy and psychotherapy outcome. Arch Gen Psychiatry. 1985;42:1081-1086.
19. Hartel DM, Schoenbaum EE, Selwyn PA, Kline J, Davenny K, Klein RS, Friedland GH. Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. Am J Public Health. 1995;85:83-88.
20. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Useful predictors of outcome in methadone-treated patients: results from a controlled clinical trial with three doses of methadone. J Maintenance Addict. In press.
21. D'Aunno T, Vaughn TE. Methadone Maintainence: Some Treatment Programs Are not Effective, Greater Federal Oversight Needed. Washington, DC: US General Accounting Office; 1990.
22. D'Aunno T, Vaughn TE. Variations in methadone treatment practices: results from a national study. JAMA. 1992;267:253-258.
23. Medical Economics Data. Physicians Desk Reference. Montvale, NJ: Medical Economics Data Production Co; 1997.
24. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:53-63.
25. Weiss RD, Martinez-Raga J, Griffin ML, Greenfield SF, Hufford C. Gender differences in cocaine dependent patients: a six-month follow-up study. Drug Alcohol Depend. 1997;44:35-40.
26. Hochberg Y, Tamhane AC. Multiple Comparison Procedures. New York, NY: John Wiley & Sons; 1987.
27. Pocock SG. Clinical Trials: A Practical Approach. New York, NY: John Wiley & Sons; 1983.
28. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis and Addiction Severity Index. J Clin Psychopharm. 1996;16:58-67.